QuiaPEG

Newsroom

Filter news by year:
Page:
1234
Nov 28, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, known as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows selection of a release time for the drug through a controllable chemical coupling unit. After receiving positive pre-clinical trial results, the company has chosen its first drug project, peg-liraglutide (QPG- 1029), which has blockbuster1 potential for the indications diabetes and obesity.

Oct 14, 2018

The Extraordinary General Meeting of QuiaPEG Pharmaceuticals Holding AB (publ) ("the Company") decided on 29thJune 2018 to establish a warrant-based incentive program for senior executives within the QuiaPEG Group through the issue of up to 1,000,000 warrants with the right to subscribe for new shares in the Company, and approval of the transfer of such options. The warrants could only be subscribed to by the company's wholly owned subsidiary, QuiaPEG Pharmaceuticals AB ("Subsidiary"), that has the entitlement and obligation to transfer the warrants to senior executives within the QuiaPEG Group on one or more occasions in accordance with the allocation decided by the Board.

Oct 12, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that, on October 10th, 2018, Steen Krøyer, Chairman of the Board, has acquired 75,000 shares at an average price of SEK 3.18, totaling SEK 238,500.

Oct 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" for granting of a patent in the United States.

Sept 27, 2018

QuiaPEG continues the commercialization of avUni-Qleaver® together with Sinopeg by exhibiting in Sinopeg's booth at the major trade fair CPHI in madrid, 9-11 october.

Sept 13, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announced that a patent application has been filed with the U.S. Patent Office. If the application is subsequently granted, QuiaPEG will obtain a patent protection to at least the end of 2038.

Sept 03, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that the company's CEO, Marcus Bosson, has on 31/8 and 3/9 in total acquired 100,000 shares at an average price of SEK 2.02 and that on 3 September, Board member Anders Vedin has acquired 99,806 shares at an average price of SEK 2.14.

Aug 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives "Notice of Allowance" regarding granting of a patent in the United States.

July 22, 2018

At the board meeting of the company held on April 26, 2018 the board of directors of QuiaPEG resolved, based on its authorization, to issue 6 000 000 warrants without consideration to the Dutch investment group, Nyenburgh Holding B.V. Each warrants provides entitlement to subscription of 1 new share in QuiaPEG with a quotient value of SEK 0.9, which means that the share capital can increase by a maximum of SEK 5 400 000 upon full exercise of the warrants through subscription of a maximum of 6 000 000 new shares. The warrants may be exercised for subscription of shares in the Company during the period from and including the day of issue of the warrants up to and including April 30, 2021. The subscription rate per share shall amount to SEK 3,50. The issue of the warrants is now registered.

June 29, 2018

The shareholders of QuiaPEG Pharmaceuticals Holding AB (publ) have held an extraordinaryshareholders’meeting on June 29, 2018.The shareholders’ meeting resolved to, among othersthings, in accordance with the board ofdirectors’proposal, introduce an incentive program by way of issue of a maximum of 1 000 000 warrants to the wholly-owned subsidiary QuiaPEG Pharmaceuticals AB and to authorize the transfer of such warrants to management and others key personnel in the company and its subsidiary. The warrants are issued without consideration.

Page:
1234
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message